DAL K45 (ATCC® CRL-2292)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: Carcinoma, Carcinoma

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Culture Properties suspension
Biosafety Level 1
Disease Carcinoma, Carcinoma
Applications
The hybridoma cell line DAL K45 secretes a mouse monoclonal antibody (IgG1) reactive with human renal cell carcinoma; it does not react significantly with normal tissues.
This antibody as well as DAL K20 (ATCC CRL-2289) and DAL 29 (ATCC CRL-2291) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models.
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line.
Derivation
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line.
Genes Expressed
immunoglobulin; monoclonal antibody; against human renal cell carcinoma
Cellular Products
immunoglobulin; monoclonal antibody; against human renal cell carcinoma
Comments
The hybridoma cell line DAL K45 secretes a mouse monoclonal antibody (IgG1) reactive with human renal cell carcinoma; it does not react significantly with normal tissues.
DAL K45 precipitates molecules with molecular weighs of 177,000 and 150,000 from extracts of surface-labeled Caki-1 (ATCC HTB-46) cells.
This antibody as well as DAL K20 (ATCC CRL-2289) and DAL 29 (ATCC CRL-2291) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models.
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG1
Name of Depositor SJ Luner, T Ghose
References

Luner SJ, et al. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res. 46: 5816-5820, 1986. PubMed: 3530441

Guha AK, et al. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model. Cancer Lett. 61: 35-43, 1991. PubMed: 1764696

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Luner SJ, et al. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res. 46: 5816-5820, 1986. PubMed: 3530441

Guha AK, et al. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model. Cancer Lett. 61: 35-43, 1991. PubMed: 1764696